NCT03866382 2026-04-16
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
National Cancer Institute (NCI)
Parabilis Medicines, Inc.
University of Wisconsin, Madison
University of Wisconsin, Madison
Maastricht University Medical Center